Nervgen Pharma Corp 6-K, filed Jan 8, 2026
Nervgen Pharma Corp. (NGEN)
About this 6-K
Nervgen Pharma Corp filed this 6-K on January 8, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2026
Commission File Number: 001-43048
NERVGEN PHARMA
CORP.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s name)
112-970 Burrard Street, Unit 1290
Vancouver, British Columbia, Canada V6Z 2R4
Telephone: (778) 731-1711
(Address and telephone number of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ¨ Form 40-F x
INCORPORATION BY REFERENCE
Exhibit 99.1 of this Form 6-K is incorporated by reference into the registrant’s Registration Statement on Form F-10 (File No. 333-292197).
DOCUMENTS INCLUDED AS PART OF THIS REPORT
| Exhibit | ||
| 99.1 | Material Change Report, dated January 8, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
NERVGEN PHARMA CORP. | ||
| Date: January 8, 2026 | By: | /s/ William J. Adams |
| Name: William J. Adams | ||
| Title: Chief Financial Officer | ||
Exhibit 99.1
Form 51-102F3
MATERIAL CHANGE REPORT
| Item 1. | Name and Address of Reporting Issuer |
NervGen Pharma Corp. (“NervGen” or the “Company”)
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
| Item 2. | Date of Material Changes |
January 8, 2026
| Item 3. | News Releases |
A news release announcing the material change was disseminated on January 8, 2026 through GlobeNewswire distribution network, and a copy was filed on NervGen’s SEDAR+ profile at www.sedarplus.ca.
| Item 4. | Summary of Material Changes |
On January 8, 2026, the Company announced the Company's common shares have been approved for listing on Nasdaq.
| Item 5. | Full Description of Material Changes |
On January 8, 2026, the Company announced the Company's common shares have been approved for listing on Nasdaq. NervGen’s common shares began trading on Nasdaq as of January 8, 2026, under the symbol “NGEN.”
| Item 6. | Reliance on subsection 7.1(2) of National Instrument 51-102 |
Not applicable.
| Item 7. | Omitted Information |
No information has been omitted on the basis that it is confidential information.
| Item 8. | Executive Officer |
William Adams, Chief Financial Officer
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
| Item 9. | Date of Report |
January 8, 2026.